---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-150146"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T17:06:28.580143+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CFO Keith Vendola departs; Brian Burkavage appointed Chief Accounting Officer

## Summary
- Keith Vendola terminated as CFO by mutual agreement effective May 9, 2022; no disagreement with company or board.
- CEO Mai-Britt Zocca will serve as Principal Financial Officer until CAO appointment.
- Brian Burkavage, previously VP of Finance, appointed Chief Accounting Officer effective May 12, 2022.
- Burkavage was Controller at Passage BIO (2020-2021) and Director of FP&A at Aclaris Therapeutics (2017-2020).

## SEC filing metadata
- accession: 0001193125-22-150146
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/d339835d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-150146
- JSON: https://secwatch.observer/filing/0001193125-22-150146.json
- Plain text: https://secwatch.observer/filing/0001193125-22-150146.txt

## Key facts
- Executive change
  Brian Burkavage was appointed as Chief Accounting Officer at IO Biotech, Inc..
  - Action: appointed
  - Role: Chief Accounting Officer
  source text: On May 12, 2022, the Company appointed Brian Burkavage, 39, the Company’s Vice President of Finance, as its Chief Accounting Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm
- Executive change
  Keith Vendola was terminated as Chief Financial Officer at IO Biotech, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On May 9, 2022, IO Biotech, Inc. (the “Company”) and Keith Vendola, Chief Financial Officer of the Company, have terminated Mr. Vendola’s employment with the Company by mutual agreement, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.